IRMD

In the past six months, IRadimed Corp. (IRMD) stock experienced a 6-month change of -18.63% as of September 23, 2026, but saw a daily increase of 9.6% on February 10, 2026. For Q4 and Full-Year 2025, the company reported record fourth-quarter revenue of $22.7 million, up 17% year-over-year, and full-year revenue of $83.8 million, a 14% increase from 2024, with Q4 2025 net income rising to $6.4 million, or $0.50 per diluted share, a 25% increase. In Q1 2026, IRadimed reported strong results with revenue of $22.0 million, up 13% from the prior year, and GAAP diluted EPS of $0.45, a 22% increase, also launching its next-generation 3870 MRI-compatible IV infusion pump and declaring a quarterly cash dividend of $0.20 per share. For Q2 2026, revenue was $20.5 million, a 0.5% increase compared to the same period in 2025, with GAAP diluted EPS of $0.41 and another quarterly cash dividend of $0.20 per share declared; for the first half of 2026, revenue increased by 6% to $42.4 million, and net income rose by 5% to $11.0 million.